Introduction
In the field of liver transplantation, matching ABO blood types between donor and recipient is the established gold standard to prevent hyperacute rejection. However, in regions where living donor liver transplantation (LDLT) is the primary modality, the donor pool is often limited to close family members, sometimes necessitating the use of an ABO-incompatible (ABO-I) donor. This paper, published in 2000 by researchers at Kyoto University, reviews a decade of experience (1991–2000) in managing 68 ABO-I transplants and the evolution of immunosuppressive strategies to overcome the high risks associated with these procedures.
The Challenge of ABO-Incompatibility
The primary barrier in ABO-I transplantation is the presence of pre-existing antibodies in the recipient against the donor's blood type. For instance, a Type O recipient receiving a Type A liver possesses anti-A antibodies that can trigger rapid graft failure, vascular thrombosis, and hepatic necrosis. Historically, these transplants were associated with poor outcomes and severe biliary complications, such as sclerosing cholangitis.
Evolution of the Kyoto Protocol
To address these risks, the Kyoto University team iteratively refined their "Kyoto Protocol." The baseline treatment of Tacrolimus (Prograf) and steroids was progressively augmented with:
- Splenectomy: Performed to reduce the population of antibody-producing B-cells.
- Pharmacological Additions: Inclusion of OKT3 (monoclonal antibody), Azathioprine (Imuran), and Cyclophosphamide (Endoxan).
- Mechanical Titer Reduction: Pre-operative plasma exchange or antibody adsorption to physically lower the concentration of anti-donor antibodies.
- Steroid Pulses: Prophylactic weekly pulses were introduced in later stages of the protocol.
Key Findings: Age and Antibody Correlations
The study revealed two critical factors influencing success: recipient age and post-transplant antibody titers.
The Impact of Age
Survival outcomes were markedly different across age groups. Pediatric patients, particularly those under one year old, showed significantly better graft survival than adults. This suggests that the immature immune systems of infants or the different vascular/biliary architecture in younger patients may offer a protective advantage against ABO-I complications.
Antibody Titers as Predictors
The researchers found that peak levels of IgM and IgG antibodies were strong predictors of specific complications. High IgM titers were predominantly linked to intrahepatic biliary complications, typically appearing 1–3 months post-operation. In contrast, high IgG titers were closely associated with hepatic necrosis, a devastating form of liver tissue death. Pre-operative peaks in IgG were particularly indicative of poor outcomes.
Results and Trade-offs
The intensive protocol (including Cyclophosphamide and steroid pulses) significantly improved the "healthy" survival rate to 73%, compared to a mere 12.5% in historical controls (p=0.0183). However, this success came with a significant cost: a dramatic increase in opportunistic infections. Cytomegalovirus (CMV) infection rates soared to 86% in the intensive immunosuppression group, compared to 37% in the standard compatible group.
Conclusion
The Kyoto University experience demonstrates that while aggressive immunosuppression can successfully mitigate the risks of ABO-incompatible liver transplantation, it creates a "double-edged sword" by increasing vulnerability to life-threatening infections. The authors conclude that future strategies must move toward risk-stratification—tailoring the intensity of immunosuppression based on individual factors like age and pre-operative antibody titers to balance graft survival with the risk of infection.
Summary updated